BioNexus Gene Lab Statistics
Share Statistics
BioNexus Gene Lab has 1.8M
shares outstanding. The number of shares has increased by 1.7%
in one year.
| Shares Outstanding | 1.8M |
| Shares Change (YoY) | 1.7% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 329,086 |
| FTD / Avg. Volume | 51.99% |
Short Selling Information
The latest short interest is 291.49K, so 16.22% of the outstanding
shares have been sold short.
| Short Interest | 291.49K |
| Short % of Shares Out | 16.22% |
| Short % of Float | 16.24% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -3.12 and the forward
PE ratio is null.
BioNexus Gene Lab's PEG ratio is
0.07.
| PE Ratio | -3.12 |
| Forward PE | n/a |
| PS Ratio | 0.52 |
| Forward PS | n/a |
| PB Ratio | 0.6 |
| P/FCF Ratio | -2.03 |
| PEG Ratio | 0.07 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for BioNexus Gene Lab.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.81,
with a Debt / Equity ratio of 0.03.
| Current Ratio | 3.81 |
| Quick Ratio | 3.1 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.15 |
| Debt / FCF | -0.09 |
| Interest Coverage | -74.42 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $317,021.53 |
| Profits Per Employee | $-53,278.07 |
| Employee Count | 30 |
| Asset Turnover | 0.91 |
| Inventory Turnover | 5.92 |
Taxes
| Income Tax | 3.49K |
| Effective Tax Rate | -0.22% |
Stock Price Statistics
The stock price has increased by -55.29% in the
last 52 weeks. The beta is 1.72, so BioNexus Gene Lab's
price volatility has been higher than the market average.
| Beta | 1.72 |
| 52-Week Price Change | -55.29% |
| 50-Day Moving Average | 2.91 |
| 200-Day Moving Average | 3.54 |
| Relative Strength Index (RSI) | 46.93 |
| Average Volume (20 Days) | 633,025 |
Income Statement
In the last 12 months, BioNexus Gene Lab had revenue of 9.51M
and earned -1.6M
in profits. Earnings per share was -0.09.
| Revenue | 9.51M |
| Gross Profit | 1.29M |
| Operating Income | -1.57M |
| Net Income | -1.6M |
| EBITDA | -1.42M |
| EBIT | -1.57M |
| Earnings Per Share (EPS) | -0.09 |
Full Income StatementBalance Sheet
The company has 4.38M in cash and 210.56K in
debt, giving a net cash position of 4.17M.
| Cash & Cash Equivalents | 4.38M |
| Total Debt | 210.56K |
| Net Cash | 4.17M |
| Retained Earnings | n/a |
| Total Assets | 10.43M |
| Working Capital | 5.48M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -2.23M
and capital expenditures 0, giving a free cash flow of -2.46M.
| Operating Cash Flow | -2.23M |
| Capital Expenditures | n/a |
| Free Cash Flow | -2.46M |
| FCF Per Share | -1.38 |
Full Cash Flow StatementMargins
Gross margin is 13.56%, with operating and profit margins of -16.55% and -16.81%.
| Gross Margin | 13.56% |
| Operating Margin | -16.55% |
| Pretax Margin | -16.77% |
| Profit Margin | -16.81% |
| EBITDA Margin | -14.94% |
| EBIT Margin | -16.55% |
| FCF Margin | -25.88% |
